Newron Pharmaceuticals (Switzerland) Analysis
NWRN Stock | CHF 6.79 0.21 3.00% |
Newron Pharmaceuticals SpA is undervalued with Real Value of 7.14 and Hype Value of 6.79. The main objective of Newron Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Newron Pharmaceuticals SpA is worth, separate from its market price. There are two main types of Newron Pharmaceuticals' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Newron Pharmaceuticals' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Newron Pharmaceuticals' stock to identify patterns and trends that may indicate its future price movements.
The Newron Pharmaceuticals stock is traded in Switzerland on SIX Swiss Exchange, with the market opening at 09:00:00 and closing at 17:30:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in Switzerland. Newron Pharmaceuticals is usually not traded on Good Friday, Berchtoldstag, Easter Monday, International Workers ' Day, Ascension Day ( 2025 ), Whitmonday ( 2025 ), National Day, Christmas Eve ( 2025 ), Christmas Day, St . Stephen 's Day, New Year 's Eve ( 2025 ), New Year 's Day. Newron Stock trading window is adjusted to Europe/Zurich timezone.
Newron |
Newron Stock Analysis Notes
The company recorded a loss per share of 0.85. Newron Pharmaceuticals had not issued any dividends in recent years. Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally. The company was founded in 1998 and is headquartered in Bresso, Italy. NEWRON PHARMA operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 24 people. To find out more about Newron Pharmaceuticals SpA contact Stefan Weber at 39 02 610 3461 or learn more at https://www.newron.com.Newron Pharmaceuticals Investment Alerts
Newron Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
The company reported the revenue of 5.76 M. Net Loss for the year was (14.9 M) with profit before overhead, payroll, taxes, and interest of 5.76 M. | |
Newron Pharmaceuticals SpA has accumulated about 58.99 M in cash with (11.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.31. |
Newron Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 81.91 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Newron Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Newron Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Newron Profitablity
Newron Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Newron Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Newron Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Newron Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Newron Pharmaceuticals' profitability requires more research than a typical breakdown of Newron Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (2.44) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.84) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.84. Technical Drivers
As of the 20th of July, Newron Pharmaceuticals secures the Downside Deviation of 1.9, risk adjusted performance of 0.0788, and Mean Deviation of 1.96. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Newron Pharmaceuticals, as well as the relationship between them. Please verify Newron Pharmaceuticals treynor ratio, value at risk, downside variance, as well as the relationship between the maximum drawdown and potential upside to decide if Newron Pharmaceuticals SpA is priced some-what accurately, providing market reflects its recent price of 6.79 per share.Newron Pharmaceuticals Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Simple Moving Average indicator is calculated by adding the closing price of Newron Pharmaceuticals for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Newron Pharmaceuticals short-term fluctuations and highlight longer-term trends or cycles.
Newron Pharmaceuticals Outstanding Bonds
Newron Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Newron Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Newron bonds can be classified according to their maturity, which is the date when Newron Pharmaceuticals SpA has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
MPLX LP 4125 Corp BondUS55336VAK61 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
MGM Resorts International Corp BondUS552953CD18 | View | |
Valero Energy Partners Corp BondUS91914JAA07 | View |
Newron Pharmaceuticals Predictive Daily Indicators
Newron Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Newron Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Newron Pharmaceuticals Forecast Models
Newron Pharmaceuticals' time-series forecasting models are one of many Newron Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Newron Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Newron Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Newron Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Newron shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Newron Pharmaceuticals. By using and applying Newron Stock analysis, traders can create a robust methodology for identifying Newron entry and exit points for their positions.
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally. The company was founded in 1998 and is headquartered in Bresso, Italy. NEWRON PHARMA operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 24 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Newron Pharmaceuticals to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Global Markets Map Now
Global Markets MapGet a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
All Next | Launch Module |
Additional Tools for Newron Stock Analysis
When running Newron Pharmaceuticals' price analysis, check to measure Newron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Newron Pharmaceuticals is operating at the current time. Most of Newron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Newron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Newron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Newron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.